New drugs and clinical trial design in advanced sarcoma: Have we made any progress?

Future Oncology

Volumn 9, Issue 10, 2013, Pages 1409-1411

  Constantinidou, Anastasia ^a   Miah, Aisha ^a   Pollack, Seth ^b   Jones, Robin L ^b  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

clinical trial design; sarcoma; systemic therapy

Indexed keywords

DOCETAXEL; DOXORUBICIN; ERIBULIN; GEMCITABINE; IFOSFAMIDE; IMATINIB; MICRORNA; PACLITAXEL; PALIFOSFAMIDE; PAZOPANIB; PLACEBO; PROTEIN TYROSINE KINASE INHIBITOR; RECEPTOR BLOCKING AGENT; RIDAFOROLIMUS; SOMATOMEDIN C RECEPTOR INHIBITOR; SUNITINIB; TRABECTEDIN; UNCLASSIFIED DRUG;

ADVANCED CANCER; ANGIOSARCOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; DRUG TREATMENT FAILURE; EWING SARCOMA; FOLLOW UP; GASTROINTESTINAL STROMAL TUMOR; HUMAN; LEIOMYOSARCOMA; LIPOSARCOMA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SARCOMA; SOFT TISSUE SARCOMA; STUDY DESIGN; SYNOVIAL SARCOMA; SYSTEMIC THERAPY; UTERUS SARCOMA;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; RESEARCH DESIGN; SARCOMA;

EID: 84885575025     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.13.132     Document Type: Review

References (12)

1. Hensley ML, Blessing JA, Degeest K et al. Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group Phase II study. Gynecol. Oncol. 109, 323-328 (2008)
2. Demetri GD, Chawla SP, von Mehren M et al. Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized Phase II study of two different schedules. J. Clin. Oncol. 27, 4188-4196 (2009)
3. Fury MG, Antonescu CR, Van Zee KJ et al. A 14-year retrospective review of angiosarcoma: clinical characteristics, prognostic factors, and treatment outcomes with surgery and chemotherapy. Cancer J. 11, 241-247 (2005) (Pubitemid 44698813)
4. van der Graaf WTA, Judson I, Verweij J et al. Results of a randomised Phase III trial (EORTC 62012) of single agent doxorubicin versus doxorubicin plus ifosfamide as first line chemotherapy for patients with advanced or metastatic soft tissue sarcoma: a survival study by the EORTC Soft Tissue and Bone Sarcoma Group. 37th European Society for Medical Oncology Congress, Vienna, Austria, 28 September-2 October 2012 (Abstract LBA7)
5. Tap WD, Demetri G, Barnette P et al. Phase II study of ganitumab, a fully human anti-type-1 insulin-like growth factor receptor antibody, in patients with metastatic Ewing family tumors or desmoplastic small round cell tumors. J. Clin. Oncol. 30, 1849-1856 (2012)
6. Pappo AS, Patel SR, Crowley J et al. R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a Phase II Sarcoma Alliance for Research through Collaboration study. J. Clin. Oncol. 29, 4541-4547 (2011)
7. Demetri GD, Chawla SP, Ray-Coquard I et al. Results of an international randomized Phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients after benefit from prior chemotherapy. J. Clin. Oncol. 31(19), 2485-2492 (2013)
8. C. F. Verschraegen SPC MMM, Ryan CW, Blakely L. Picasso Study Investigators: a Phase II, randomized, controlled trial of palifosfamide plus doxorubicin versus doxorubicin in patients with soft tissue sarcoma (PICASSO). J. Clin. Oncol. 28(15s Suppl.) Abstract 10004 (2010)
9. Schoffski P, Ray-Coquard IL, Cioffi A et al. Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes. Lancet Oncol. 12, 1045-1052 (2011)
10. Agnieszka Wozniak EACW, Herman Burger, Joke Allemeersch et al. Identification of potential molecular biomarkers for response of soft tissue sarcoma to eribulin: translational results of EORTC trial 62052. American Society of Clinical Oncology Annual Meeting, Chicago, IL, USA, 30 May-3 June 2013
11. Amiri-Kordestani L, Fojo T. Why do Phase III clinical trials in oncology fail so often? J. Natl Cancer Inst. 104, 568-569 (2012)
12. Gan HK, You B, Pond GR et al. Assumptions of expected benefits in randomized Phase III trials evaluating systemic treatments for cancer. J. Natl Cancer Inst. 104, 590-598 (2012).